Background
Methods
Patient cohort
Statistical analysis
Results
Patients’ baseline characteristics
Variable | CA19–9 (U/ml) | CA72–4 (U/ml) | CEA (ug/L) | Cyfra21–1 (ng/ml) | SCC-Ag (ng/ml) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
< 37(%) | ≥37(%) |
p
| < 6(%) | ≥6(%) |
p
| < 5(%) | ≥5(%) |
p
| < 3.4(%) | ≥3.4(%) |
p
| < 1.5(%) | ≥1.5(%) |
p
| |
Age(y) | 0.613 | 0.806 | 0.010 | 0.013 | 0.215 | ||||||||||
< 60 | 187 (46.6) | 6 (40.0) | 177 (46.6) | 16 (44.4) | 190 (47.7) | 3 (16.7) | 157 (49.8) | 36 (35.6) | 156 (48.0) | 37 (40.7) | |||||
≥ 60 | 214 (53.4) | 9 (60.0) | 203 (53.4) | 20 (55.6) | 208 (52.3) | 15 (83.3) | 158 (50.2) | 65 (64.4) | 169 (52.0) | 54 (59.3) | |||||
Gender | 0.507 | 0.606 | 0.721 | 0.271 | 0.349 | ||||||||||
Male | 322 (80.3) | 11 (73.3) | 303 (79.7) | 30 (83.3) | 318 (79.9) | 15 (83.3) | 256 (81.3) | 77 (76.2) | 257 (79.1) | 76 (83.5) | |||||
Female | 79 (19.7) | 4 (26.7) | 77 (20.3) | 6 (16.7) | 80 (20.1) | 3 (16.7) | 59 (18.7) | 24 (23.8) | 68 (20.9) | 15 (16.5) | |||||
Tumor length | 0.117 | 0.015 | 0.127 | 0.067 | < 0.001 | ||||||||||
< 4 | 161 (40.1) | 3 (20.0) | 143 (37.6) | 21 (58.3) | 160 (40.2) | 4 (22.2) | 132 (41.9) | 32 (31.7) | 143 (44.0) | 21 (23.1) | |||||
≥ 4 | 240 (59.9) | 12 (80.0) | 237 (62.4) | 15 (41.7) | 238 (59.8) | 14 (77.8) | 183 (58.1) | 69 (68.3) | 182 (56.0) | 70 (76.9) | |||||
Tumor location | 0.842 | 0.461 | 0.930 | 0.594 | 0.369 | ||||||||||
Upper | 32 (8.0) | 1 (6.7) | 29 (7.6) | 4 (11.1) | 32 (8.0) | 1 (5.6) | 27 (8.6) | 6 (5.9) | 29 (8.9) | 4 (4.4) | |||||
Middle | 237 (59.1) | 10 (66.7) | 229 (60.3) | 18 (50.0) | 236 (59.3) | 11 (61.1) | 188 (59.7) | 59 (58.4) | 191 (58.8) | 56 (61.5) | |||||
Lower | 132 (32.9) | 4 (26.7) | 122 (32.1) | 14 (38.9) | 130 (32.7) | 6 (33.3) | 100 (31.7) | 36 (35.6) | 105 (32.3) | 31 (34.1) | |||||
Differentiation | 0.555 | 0.634 | 0.372 | 0.299 | 0.050 | ||||||||||
Well-moderate | 323 (80.5) | 13 (86.7) | 308 (81.1) | 28 (77.8) | 320 (80.4) | 16 (88.9) | 258 (81.9) | 78 (77.2) | 256 (78.8) | 80 (87.9) | |||||
Poor | 78 (19.5) | 2 (13.3) | 72 (18.9) | 8 (22.2) | 78 (19.6) | 2 (11.1) | 57 (18.1) | 23 (22.8) | 69 (21.2) | 11 (12.1) | |||||
pT category | 0.475 | 0.679 | 0.467 | 0.355 | 0.051 | ||||||||||
pT1 | 25 (6.2) | 0 (0.0) | 23 (6.1) | 2 (5.6) | 25 (6.3) | 0 (0) | 22 (7.0) | 3 (3.0) | 22 (6.8) | 3 (3.3) | |||||
pT2 | 100 (24.9) | 2 (13.3) | 92 (24.2) | 10 (27.8) | 99 (24.9) | 3 (16.7) | 80 (25.4) | 22 (21.8) | 88 (27.1) | 14 (15.4) | |||||
pT3 | 74 (18.5) | 3 (20.0) | 73 (19.2) | 4 (11.1) | 74 (18.6) | 3 (16.7) | 58 (18.4) | 19 (18.8) | 57 (17.5) | 20 (22.0) | |||||
pT4 | 202 (50.4) | 10 (66.7) | 192 (50.5) | 20 (55.6) | 200 (50.3) | 12 (66.7) | 155 (49.2) | 57 (56.4) | 158 (48.6) | 54 (59.3) | |||||
pN category | 0.280 | 0.443 | 0.001 | 0.007 | < 0.001 | ||||||||||
pN0 | 210 (52.4) | 4 (26.7) | 199 (52.4) | 15 (41.7) | 211 (53.0) | 3 (16.7) | 176 (55.9) | 38 (37.6) | 184 (56.6) | 30 (33.0) | |||||
pN1 | 141 (35.2) | 8 (53.3) | 132 (34.7) | 17 (47.2) | 139 (34.9) | 10 (55.6) | 105 (33.3) | 44 (43.6) | 111 (34.2) | 38 (41.8) | |||||
pN2 | 33 (8.2) | 2 (13.3) | 33 (8.7) | 2 (5.6) | 30 (7.5) | 5 (27.8) | 24 (7.6) | 11 (10.9) | 20 (6.2) | 15 (16.5) | |||||
pN3 | 17 (4.2) | 1 (6.7) | 16 (4.2) | 2 (5.6) | 18 (4.5) | 0 (0.0) | 10 (3.2) | 8 (7.9) | 10 (3.1) | 8 (8.8) | |||||
TNM stage | 0.361 | 0.773 | 0.075 | 0.070 | < 0.001 | ||||||||||
I | 22 (5.5) | 0 (0.0) | 21 (5.5) | 1 (2.8) | 22 (5.5) | 0 (0.0) | 20 (6.3) | 2 (2.0) | 21 (6.5) | 1 (1.1) | |||||
II | 125 (31.2) | 3 (20.0) | 117 (30.8) | 11 (30.6) | 126 (31.7) | 2 (11.1) | 102 (32.4) | 26 (25.7) | 112 (34.5) | 16 (17.6) | |||||
III | 254 (63.3) | 12 (80.0) | 242 (63.7) | 24 (66.7) | 250 (62.8) | 16 (88.9) | 193 (61.3) | 73 (72.3) | 192 (59.1) | 74 (81.3) | |||||
PC | 0.994 | 0.400 | 0.928 | 0.088 | 0.575 | ||||||||||
Yes | 241 (60.1) | 9 (60.0) | 226 (59.5) | 24 (66.7) | 239 (60.1) | 11 (61.1) | 182 (57.8) | 68 (67.3) | 193 (59.4) | 57 (62.6) | |||||
No | 160 (39.9) | 6 (40.0) | 154 (40.5) | 12 (33.3) | 159 (39.9) | 7 (38.9) | 133 (42.2) | 33 (32.7) | 132 (40.6) | 34 (37.4) |
Prognostic value of tumor biomarkers
Variable | Overall survival | |||
---|---|---|---|---|
Univariate | Multivariate | |||
HR (95% CI) |
p
| HR (95% CI) |
p
| |
Age(y) | 0.362 | |||
< 60 | 1 | |||
≥ 60 | 1.127 (0.871–1.459) | |||
Gender | 0.011 | 0.010 | ||
Male | 1 | 1 | ||
Female | 0.630 (0.441–0.898) | 0.624 (0.435–0.894) | ||
Tumor length (cm) | < 0.001 | 0.257 | ||
< 4 | 1 | 1 | ||
≥ 4 | 1.665 (1.266–2.190) | 1.182 (0.885–1.579) | ||
Tumor location | 0.772 | |||
Upper | 1 | |||
Middle | 1.085 (0.672–1.752) | |||
Lower | 0.983 (0.594–1.627) | |||
Differentiation | 0.982 | |||
Well - moderate | 1 | |||
Poor | 1.004 (0.725–1.390) | |||
pT category | < 0.001 | < 0.001 | ||
T1 | 1 | 1 | ||
T2 | 2.000 (0.786–5.090) | 1.893 (0.739–4.847) | ||
T3 | 3.456 (1.365–8.747) | 3.017 (1.171–7.772) | ||
T4 | 5.604 (2.297–13.671) | 4.674 (1.887–11.577) | ||
pN category | < 0.001 | < 0.001 | ||
pN0 | 1 | 1 | ||
pN1 | 2.469 (1.856–3.286) | 2.331 (1.732–3.316) | ||
pN2 | 2.801 (1.805–4.347) | 2.949 (1.840–4.725) | ||
pN3 | 3.487 (2.015–6.035) | 3.461 (1.960–6.109) | ||
TNM stage | < 0.001 | |||
I | 1 | |||
II | 1.974 (0.709–5.500) | |||
III | 6.010 (2.231–16.192) | |||
Postoperative chemotherapy | 0.015 | < 0.001 | ||
Yes | 1 | 1 | ||
No | 1.376 (1.063–1.780) | 1.935 (1.468–2.549) | ||
CA19–9 | 0.001 | 0.018 | ||
< 37 | 1 | 1 | ||
≥ 37 | 2.754 (1.535–4.938) | 2.130 (1.138–3.986) | ||
CA72–4 | 0.799 | |||
< 6 | 1 | |||
≥ 6 | 0.942 (0.596–1.490) | |||
CEA | < 0.001 | 0.022 | ||
< 5 | 1 | 1 | ||
≥ 5 | 3.512 (2.159–5.713) | 1.827 (1.089–3.064) | ||
Cyfra21–1 | 0.018 | 0.166 | ||
< 3.4 | 1 | 1 | ||
≥ 3.4 | 1.409 (1.061–1.871) | 1.238 (0.915–1.676) | ||
SCC-Ag | 0.010 | 0.631 | ||
< 1.5 | 1 | 1 | ||
≥ 1.5 | 1.472 (1.096–1.975) | 0.926 (0.677–1.267) |